Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Miami Beach, Florida 33140


Purpose:

Amifostine is a radioprotective drug which is approved by the US FDA for administration prior to each radiation treatment using the intravenous route. The study evaluated the safety of amifostine administered subcutaneously. The four targeted toxicities were nausea/vomiting, hypotension, generalized skin rash, and injection-site skin reactions.


Criteria:

Inclusion Criteria: - Institutional criteria for administration of amifostine - Radiation therapy - ECOG PS of at least 2 - No distant mets - Granulocyte count greater than 2000 - Platelet count greater than 100,000 - Creatinine less than 2.0 Exclusion Criteria: - Allergy to amifostine - Life expectancy less than 6 mos - Investigational drug within last 4 weeks


NCT ID:

NCT00158041


Primary Contact:

Principal Investigator
Michael A Samuels, MD
Mt. Sinai Medical Center


Backup Contact:

N/A


Location Contact:

Miami Beach, Florida 33140
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.